[go: up one dir, main page]

CY1112946T1 - 4-υδροξυβενζομορφανια - Google Patents

4-υδροξυβενζομορφανια

Info

Publication number
CY1112946T1
CY1112946T1 CY20121100677T CY121100677T CY1112946T1 CY 1112946 T1 CY1112946 T1 CY 1112946T1 CY 20121100677 T CY20121100677 T CY 20121100677T CY 121100677 T CY121100677 T CY 121100677T CY 1112946 T1 CY1112946 T1 CY 1112946T1
Authority
CY
Cyprus
Prior art keywords
hydroxybenzomorphania
hydroxybenzomorphs
thiocarboxamide
antipsychotics
anticonvulsants
Prior art date
Application number
CY20121100677T
Other languages
English (en)
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytechnic Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytechnic Institute filed Critical Rensselaer Polytechnic Institute
Publication of CY1112946T1 publication Critical patent/CY1112946T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Τα 4-υδροξυβενζομορφάνια τα οποία περιέχουν καρβοξαμίδιο ή θειοκαρβοξαμίδιο στην 3-θέση είναι χρήσιμα ως αναλγητικά, αντιδιαρροϊκά μέσα, αντισπασμωδικά, αντιβηχικά και φάρμακα κατά του εθισμού.
CY20121100677T 2004-11-05 2012-07-31 4-υδροξυβενζομορφανια CY1112946T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
EP10008474A EP2251330B1 (en) 2004-11-05 2005-11-03 4-Hydroxybenzomorphans

Publications (1)

Publication Number Publication Date
CY1112946T1 true CY1112946T1 (el) 2016-04-13

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100677T CY1112946T1 (el) 2004-11-05 2012-07-31 4-υδροξυβενζομορφανια

Country Status (20)

Country Link
US (7) US7262298B2 (el)
EP (2) EP2251330B1 (el)
JP (3) JP5198067B2 (el)
KR (1) KR101115841B1 (el)
CN (1) CN101090891B (el)
AT (1) ATE557006T1 (el)
AU (1) AU2005304950B2 (el)
BR (1) BRPI0517091B8 (el)
CA (1) CA2587074C (el)
CY (1) CY1112946T1 (el)
DK (1) DK2251330T3 (el)
ES (1) ES2387737T3 (el)
IL (1) IL182983A (el)
MX (1) MX2007005389A (el)
NO (1) NO340204B1 (el)
PL (1) PL2251330T3 (el)
PT (1) PT2251330E (el)
RU (2) RU2415131C2 (el)
SI (1) SI2251330T1 (el)
WO (1) WO2006052710A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572332T3 (es) * 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
CA2587074C (en) 2004-11-05 2012-09-04 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
WO2007014137A2 (en) 2005-07-21 2007-02-01 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
EP2189460B1 (en) 2007-05-04 2014-04-23 Mallinckrodt LLC Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates
US8729266B2 (en) 2007-07-17 2014-05-20 Mallinckrodt Llc Preparation of N-alkylated opiates by reductive amination
CA2694497C (en) 2007-08-09 2016-07-12 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
NZ607842A (en) 2008-09-30 2013-12-20 Mallinckrodt Llc Processes for the selective amination of ketomorphinans
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
WO2010107457A1 (en) * 2009-03-19 2010-09-23 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
WO2010118274A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-keto, 3-alkoxy morphinans
WO2010144640A2 (en) 2009-06-11 2010-12-16 Mallinckrodt Inc. Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer
ES2598496T3 (es) 2009-06-11 2017-01-27 Mallinckrodt Llc Preparación de 6-alfa-amino morfinanos N-sustituidos por transferencia de hidrógeno catalítico
JP5691042B2 (ja) 2009-12-04 2015-04-01 アルカーメス ファーマ アイルランド リミテッド 薬物過量摂取の治療のためのモルヒナン誘導体
ES2582306T3 (es) 2010-03-22 2016-09-12 Rensselaer Polytechnic Institute Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides
ES2527315T3 (es) * 2010-04-29 2015-01-22 Mallinckrodt Llc Preparación de compuestos morfinano con cetona saturada que tienen un bajo contenido en metal
EP2590649B1 (en) 2010-07-08 2018-11-28 Alkermes Pharma Ireland Limited Process for the synthesis of substituted morphinans
DK3446565T3 (da) * 2010-08-23 2024-01-22 Alkermes Pharma Ireland Ltd Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
US9029543B2 (en) 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
PL2718294T3 (pl) 2011-06-09 2019-04-30 SpecGx LLC Redukcyjne aminowanie 6-keto morfinanów przez katalityczne przeniesienie wodoru
DK2725908T3 (en) 2011-06-29 2017-09-11 Alkermes Inc PERIPHERALLY EFFECTIVE OPIOID COMPOUNDS
PL2753622T3 (pl) 2011-09-08 2016-07-29 SpecGx LLC Wytwarzanie alkaloidów bez oddzielania związków pośrednich
EA030609B8 (ru) 2011-12-15 2018-10-31 Алкермес Фарма Айэленд Лимитед Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9133125B2 (en) 2013-05-24 2015-09-15 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2018229062A1 (en) * 2017-03-02 2019-09-26 Ube Industries, Ltd. Therapeutic agent for alcohol use disorders
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
CN113248435B (zh) * 2020-02-13 2024-06-04 上海翰森生物医药科技有限公司 3-甲酰胺基-4-羟基纳曲酮氘代衍生物、其制备方法及其在医药上的应用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR102663533B1 (ko) * 2021-11-09 2024-05-08 백미선 레이저 치료기기용 온냉각장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
HUP9900974A3 (en) 1996-01-10 2000-09-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
ES2572332T3 (es) 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
CA2587074C (en) * 2004-11-05 2012-09-04 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans

Also Published As

Publication number Publication date
CA2587074A1 (en) 2006-05-18
RU2010147915A (ru) 2012-05-27
US20130231361A1 (en) 2013-09-05
EP2251330B1 (en) 2012-05-09
US20160075658A1 (en) 2016-03-17
NO340204B1 (no) 2017-03-20
PT2251330E (pt) 2012-07-20
EP2251330A1 (en) 2010-11-17
DK2251330T3 (da) 2012-08-06
US8802655B2 (en) 2014-08-12
IL182983A0 (en) 2007-08-19
ES2387737T3 (es) 2012-10-01
KR20070085723A (ko) 2007-08-27
AU2005304950B2 (en) 2010-12-09
US20140148475A1 (en) 2014-05-29
JP5198067B2 (ja) 2013-05-15
MX2007005389A (es) 2007-12-07
US20060111384A1 (en) 2006-05-25
JP2016020364A (ja) 2016-02-04
JP6058981B2 (ja) 2017-01-11
BRPI0517091B8 (pt) 2021-05-25
IL182983A (en) 2012-06-28
US20240092740A1 (en) 2024-03-21
RU2007120759A (ru) 2008-12-10
JP2013067636A (ja) 2013-04-18
US7262298B2 (en) 2007-08-28
SI2251330T1 (sl) 2012-09-28
RU2480455C2 (ru) 2013-04-27
EP1817291A1 (en) 2007-08-15
KR101115841B1 (ko) 2012-03-09
BRPI0517091A (pt) 2008-09-30
WO2006052710A1 (en) 2006-05-18
CN101090891B (zh) 2012-08-01
NO20072839L (no) 2007-08-03
CA2587074C (en) 2012-09-04
US20070238748A1 (en) 2007-10-11
BRPI0517091B1 (pt) 2019-10-08
RU2415131C2 (ru) 2011-03-27
PL2251330T3 (pl) 2012-12-31
AU2005304950A1 (en) 2006-05-18
US8680112B2 (en) 2014-03-25
CN101090891A (zh) 2007-12-19
JP2008519035A (ja) 2008-06-05
ATE557006T1 (de) 2012-05-15
US20150011768A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
CY1112946T1 (el) 4-υδροξυβενζομορφανια
DE60208177D1 (de) Propylenpolymerzusammensetzung, formkörper und polyolefincopolymer
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
EP1900207A4 (en) CREATING STANDARDIZED PLAYLISTS AND MAINTAINING COHERENCE
DE60328481D1 (de) Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
CY2013004I2 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
ATE407967T1 (de) Nukleierungsmittel
NO2015013I2 (no) Cabazitaxel acetonat
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
ATE264863T1 (de) 28-epirapaloge
DE60131138D1 (de) Antibakterielle mittel
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1109468T1 (el) Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια
BR0212250B1 (pt) produto de cuidado pessoal.
NO20053556D0 (no) Polymerkonjugater av interferon-beta med forbedret biologisk potens.
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
DE602006012410D1 (de) Kosmetische und/oder dermatologische Zusammensetzung mit Bornitrid
DE60312211D1 (de) Haarbehandlungsmittel
EP1426370A4 (en) PROPANOLAMINE DERIVATIVE WITH 1,4-BENZODIOXANE CORE
SE9904377D0 (sv) Pharmaceutical combinations
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
ITMI20030385A1 (it) Composizione cosmetica comprendente poliisoprene.
UY28344A1 (es) Nuevos compuestos